Clinical Trial

Liver Cancer Disparities in American Indian and Alaska Native Persons

Recruiting Phase 2
View on ClinicalTrials.gov →
Record status
This record was last updated June 4, 2024 (before its estimated September 1, 2025 completion). Its status may not reflect the trial's current state.
Summary
We are performing a pilot and feasibility randomized controlled trial (RCT) of HCC screening by US + AFP every 6 months (n=100), the current standard-of-care, versus aMRI + AFP every 6 months (n=100) for 12 months (i.e. at time 0, 6 and 12 months) among AI/AN patients with cirrhosis or HBV.
Protocol Amendment History 2 amendments
This ClinicalTrials.gov record has been amended 2 times since 2022-03-22; most recent amendment 2024-06-03.
Trial Details
NCT Number NCT05304234
Lead Sponsor University of Washington
Collaborators: National Cancer Institute (NCI), Cherokee Nation Health Services, Alaska Native Tribal Health Consortium
Conditions Hepatocellular Carcinoma, Cirrhosis, Liver, Hepatitis B
Enrollment 200 participants
Start Date 2022-04-01
Primary Completion 2025-09-01 (estimated)
Study Completion 2026-09-01 (estimated)
Updated on ClinicalTrials.gov 2024-06-04